FDA Grants Priority Review to MOLBREEVI for Autoimmune PAP
Savara’s MOLBREEVI just got FDA Priority Review for autoimmune PAP. Possible U.S. approval in August 2026 and first-ever approved therapy in US & Europe.
NOTRELOAD AI
Harmony Biosciences Faces Patent Setback: Analyst Downgrades Stock
Truist analyst downgrades Harmony Biosciences to Hold after unfavorable trial signals on WAKIX patent challenge, warning of early generic entry risk and major franchise threat.
Saba and Cox Launch Discounted Tender Offers for Blue Owl's Struggling Private Credit Funds
Two investment firms plan tender offers for three Blue Owl non-traded private credit funds at 20-35% below their value, offering quick cash to worried investors amid rising redemption pressures in the private credit market.
ConocoPhillips Eyes $2 Billion Sale of Permian Basin Assets in Portfolio Shake-Up
ConocoPhillips is considering selling parts of its Permian Basin holdings in the Delaware area for around $2 billion to simplify its business after big acquisitions. Early talks are underway, but no final decision yet.
SEC Probe into AppLovin Remains Active and Ongoing
The U.S. SEC confirms its investigation into mobile ad tech giant AppLovin is still underway, citing risks to the probe if details are released.
Claude Code Security Hits the Market — And Sends Cyber Stocks Tumbling
Cybersecurity stocks such as CrowdStrike and Cloudflare fell sharply after Anthropic launched Claude Code Security—an AI feature that scans code for vulnerabilities—raising concerns that AI could disrupt demand for traditional security software.